Recruiting the 2-5A system for antisense therapeutics.
Torrence
P F
PF
Section on Biomedical Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-0805, USA.
Xiao
W
W
Li
G
G
Cramer
H
H
Player
M R
MR
Silverman
R H
RH
D000227:Adenine Nucleotides / Q000378:metabolism* / Q000494:pharmacology; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology; D001692:Biological Transport; D017076:Computer-Aided Design; D015195:Drug Design; D004722:Endoribonucleases / Q000378:metabolism*; D004789:Enzyme Activation / Q000187:drug effects; D006801:Humans; D046911:Macromolecular Substances; D016376:Oligonucleotides, Antisense / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D009843:Oligoribonucleotides / Q000378:metabolism* / Q000494:pharmacology; D009994:Osmolar Concentration; D012333:RNA, Messenger / Q000378:metabolism; D012367:RNA, Viral / Q000037:antagonists & inhibitors / Q000235:genetics; D012136:Respiratory Syncytial Viruses / Q000187:drug effects / Q000235:genetics
D000227:Adenine Nucleotides; D000998:Antiviral Agents; D046911:Macromolecular Substances; D016376:Oligonucleotides, Antisense; D009843:Oligoribonucleotides; D012333:RNA, Messenger; D012367:RNA, Viral; C023505:2',5'-oligoadenylate; D004722:Endoribonucleases; C031956:2-5A-dependent ribonuclease